<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1149">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03091920</url>
  </required_header>
  <id_info>
    <org_study_id>C1973-202</org_study_id>
    <nct_id>NCT03091920</nct_id>
  </id_info>
  <brief_title>Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension</brief_title>
  <official_title>A Phase 2 Study to Compare the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 2 Dose Regimens of IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ironwood Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ironwood Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD)
      effects of 2 treatment regimens of IW-1973 Tablet (40 mg per day) administered orally for 2
      weeks to patients with stable type 2 diabetes mellitus and hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The number and percentage of all on-study deaths, all Serious Adverse Events (SAEs), and Treatment-Emergent Adverse Events (TEAEs).</measure>
    <time_frame>42 Days</time_frame>
    <description>The number and percentage of all on-study deaths, all Serious Adverse Events (SAEs), and Treatment-Emergent Adverse Events (TEAEs). SAEs and TEAEs will be tabulated according to MedDRA System Organ Class and Preferred Term.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change from baseline in 24-hour systolic blood pressure (BP) from ambulatory BP monitoring by dose group compared with PBO during the 14-day dosing period.</measure>
    <time_frame>Day -1 (pre-dose), and Days 1, 7, and 14</time_frame>
    <description>Change from baseline in 24-hour systolic blood pressure (BP) from ambulatory BP monitoring by dose group compared with PBO during the 14-day dosing period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration time curve during a dosing interval (AUCtau).</measure>
    <time_frame>BID Day 1 (AM and PM) and Day 7 (AM) time points 0, 1, 3, 6, and 12 hours post-dose; QD Day 1 time points 0, 1, 3, 6, 12, 13, 15, 18, and 24 hours post-dose, Day 7 and Day 14 time points 0, 1, 3, 6, 12, and 24 hours post-dose</time_frame>
    <description>Area under the plasma concentration time curve during a dosing interval (AUCtau).</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration time curve from time zero to the last measurable plasma concentration (AUClast).</measure>
    <time_frame>Time Frame: Day 14 (final dose) time points 0, 1, 3, 6, 12, 24 hours, 7 days (Day 21), and 28 days (Day 42)</time_frame>
    <description>Area under the plasma concentration time curve from time zero to the last measurable plasma concentration (AUClast).</description>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration time curve extrapolated to infinity (AUCinf).</measure>
    <time_frame>Day 14 (final dose) time points 0, 1, 3, 6, 12, 24 hours, 7 days (Day 21), and 28 days (Day 42</time_frame>
    <description>Area under the plasma concentration time curve extrapolated to infinity (AUCinf).</description>
  </other_outcome>
  <other_outcome>
    <measure>Maximum plasma concentration (Cmax).</measure>
    <time_frame>BID Day 1 (AM and PM) and Day 7 (AM) time points 1, 3, and 6 hours post-dose; QD Day 1, 7, 8, and 14 time points 1, 3, and 6 hours post-dose</time_frame>
    <description>Maximum plasma concentration (Cmax).</description>
  </other_outcome>
  <other_outcome>
    <measure>Trough plasma concentrations at the end of the dosing interval (Ctrough).</measure>
    <time_frame>BID Day 1 (AM and PM) and Day 7 (AM and PM) at 12 hours post-dose; QD Day 1, 7, 8, and 14 at 24 hours post-dose</time_frame>
    <description>Trough plasma concentrations at the end of the dosing interval (Ctrough).</description>
  </other_outcome>
  <other_outcome>
    <measure>Time of maximum plasma concentrations (Tmax).</measure>
    <time_frame>BID Day 1 (AM and PM) and Day 7 (AM) time points 1, 3, and 6 hours post-dose; QD Day 1, 7, 8, and 14 time points 1, 3, and 6 hours post-dose</time_frame>
    <description>Time of maximum plasma concentrations (Tmax).</description>
  </other_outcome>
  <other_outcome>
    <measure>Apparent terminal elimination phase half-life (t1/2).</measure>
    <time_frame>Day 14 (final dose) time points 12 hours, 24 hours, 7 days (Day 21), and 28 days (Day 42)</time_frame>
    <description>Apparent terminal elimination phase half-life (t1/2).</description>
  </other_outcome>
  <other_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vz/F).</measure>
    <time_frame>Day 14 (final dose) time points 0, 1, 3, 6, 12, 24 hours, 7 days (Day 21), and 28 days (Day 42)</time_frame>
    <description>Apparent volume of distribution during the terminal phase (Vz/F).</description>
  </other_outcome>
  <other_outcome>
    <measure>Apparent total body clearance (CL/F).</measure>
    <time_frame>Day 14 (final dose) time points 0, 1, 3, 6, 12, and 24 hours</time_frame>
    <description>Apparent total body clearance (CL/F).</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>QD/QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: IW-1973 + Placebo
On Days 1-14: 40 mg taken once daily (QD) in AM and placebo taken QD in PM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BID/QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: IW-1973 + Placebo
On Days 1-7: 20 mg taken in AM and 20 mg taken in PM. On Days 8-14: 40 mg taken QD in AM and placebo taken QD in PM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PBO/PBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Matching Placebo Oral Tablet
On Days 1-14: Placebo taken in AM and in PM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-1973 Oral Tablet</intervention_name>
    <description>40 mg QD doses of IW-1973</description>
    <arm_group_label>QD/QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IW-1973 Oral Tablet</intervention_name>
    <description>20 mg BID and 40 mg QD doses of IW-1973</description>
    <arm_group_label>BID/QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo Oral Tablet to Match Experimental Drug</description>
    <arm_group_label>QD/QD</arm_group_label>
    <arm_group_label>BID/QD</arm_group_label>
    <arm_group_label>PBO/PBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is ambulatory male or female

          -  Patient's body mass index score is &gt;20 and &lt;40 kg/m2 at the Screening Visit

          -  Women of childbearing potential must have a negative pregnancy test at the time of
             screening and check-in and must agree to use protocol-specified contraception
             throughout the duration of the study

          -  Patient's health is stable with no clinically significant findings on physical
             examination

          -  Patient has type 2 (ie, adult onset) diabetes mellitus diagnosed by a physician or
             nurse practitioner &gt; 6 months before the Screening Visit, is on a stable glycemic
             control medication, and protocol specified HbA1c values at the Screening Visit

          -  Patient has hypertension diagnosed by a physician or nurse practitioner &gt; 6 months
             before the Screening Visit, and BP within the protocol's acceptable range

          -  Patients must be on a stable regimen for hypertension control that includes an
             angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)

          -  Other inclusion criteria per protocol

        Exclusion Criteria:

          -  Patient has a clinically significant active or unstable medical condition that, in
             the opinion of the Investigator, would preclude trial participation

          -  Patient is on medication(s) that, when co-administered with a soluble guanylate
             cyclase (sGC) stimulator, could increase the risk of hypotension

          -  Patient has evidence of severe or active end-organ damage

          -  Patient is an active smoker or has used any nicotine-containing products (cigarettes,
             e-cigarettes, vape pens, cigars, chewing tobacco, gum, patches) during the 6 months
             before Check-in. Use of nicotine is excluded during the study until after the End of
             Trial Visit.

          -  Other exclusion criteria per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ProSciento, Inc.</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Sanchez</last_name>
      <phone>619-427-1300</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>March 8, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
